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Background: Rhodiola rosea (Rhodiola) is a plant in the Crassulaceae family that grows in cold regions of the
world. It is mainly used in clinics as an adaptogen. Recently, it has been mentioned that Rhodiola increases plasma
β-endorphin to lower blood pressure. Thus, the present study aims to investigate the antidiabetic action of Rhodiola
in relation to opioids in streptozotocin-induced diabetic rats (STZ-diabetic rats).
Methods: In the present study, the plasma glucose was analyzed with glucose oxidase method, and the determination
of plasma β-endorphin was carried out using a commercially available enzyme-linked immunosorbent assay. The
adrenalectomy of STZ-diabetic rats was used to evaluate the role of β-endorphin. In addition, quantitative reverse
transcription-polymerase chain reaction (qRT-PCR) and western blotting analysis were performed to investigate mRNA
and protein expressions.
Results: Rhodiola-water extract dose-dependently lowered the plasma glucose in STZ-diabetic rats and this action was
reversed by blockade of opioid μ-receptors using cyprodime. An increase of plasma β-endorphin by rhodiola-water
extract was also observed in same manner. The plasma glucose lowering action of rhodiola-water extract was
attenuated in bilateral adrenalectomized rats. In addition, continuous administration of rhodiola-water extract for 3
days in STZ-diabetic rats resulted in an increased expression of glucose transporter subtype 4 (GLUT 4) in skeletal
muscle and a marked reduction of phosphoenolpyruvate carboxykinase (PEPCK) expression in liver. These effects
were also reversed by blockade of opioid μ-receptors.
Conclusions: Taken together, rhodiola-water extract improves hyperglycemia via an increase of β-endorphin secretion
from adrenal gland to activate opioid μ-receptors in STZ-diabetic rats.
Keywords: Adrenalectomy, Hyperglycemia, Opioid μ-receptor, Plasma glucose, Rhodiola-water extractBackground
Diabetes mainly results from dysfunction of glucose
homeostasis and causes many complications, including
cardiovascular diseases, neurological complication, chronic
renal failure, and diabetic retinopathy [1-4]. Hyperglycemia
is correlated with an increased risk of short-term acute
complications, such as hyperosmolar coma, and long-term
complications affecting the micro and macrovasculature
[5,6]. In general, oral administration of antidiabetic agents,
caloric restrictions, regular exercise and lifestyle are often
applied to control hyperglycemia [7-9]. Recently, the man-
agement of diabetic hyperglycemia has attracted much
attention in alternative therapy [10,11]. Moreover, herbal* Correspondence: ncs838@yahoo.com.tw
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stated.supplements and other alternative medicine for handling
of diabetic hyperglycemia are necessary.
Rhodiola rosea (Rhodiola) belongs to Crassulaceae
family that is grown at high altitudes and northern lati-
tudes and this herb is mentioned to reduce fatigue, im-
prove physical activity and alleviate depression [12,13].
The documented hydrophilic extracts from Rhodiola
contain many chemical compositions and they have been
identified, including cinnamic alcohol, chlorogenic acid,
rhodiooctanoside, rosiridin, rosavin and the phenolic
compounds salidroside, rhodiolin in addition to a novel
compound consisting of viridoside with an attached
arabinose unit (mongrhoside) [13,14]. In recent years,
rhodiola-water extract has been reported to improve
hypertension via the release of β-endorphin in animal
model [15]. Otherwise, involvement of β-endorphin or. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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products has been mentioned [16,17]. Actually, some
chemical agents or exogenous β-endorphin might
improve hyperglycemia through an activation of opioid
μ-receptors in STZ-diabetic rats lacking insulin [18-20].
However, antihyperglycemic action of rhodiola-water
extract remained obscure. In the present study,
rhodiola-water extract is used to screen the effect on
hyperglycemia in diabetic rats. Also, the mediation of




The radix of Rhodiola Rosea (Crassulaceae) originated
from Qinghai-Tibet plateau of China was donated
from Giu Ding Biotechnology Co., Ltd., Taiwan and was
authenticated by Professor I-Min Liu (Department of
Pharmacy, Tajen University). The dried voucher speci-
men (No. GiuDing 94001) was deposited in the herbar-
ium of the college of pharmacy, Tajen University
(Pingtung, Taiwan).
Preparation of plant extracts
The air-dried chopped plant radix (150 g) was extracted
exhaustively by maceration with in distilled water (1 L)
by stirring (Harmony Hot Plate Stirrer, Japan) at 55°C
for 7 h (three times) and The extracts were sieved using
a muslin cloth and then filtered under suction pressure
with a filter paper. They were then concentrated under
reduced pressure at 50°C using a rotary evaporator
(Buchi, Switzerland). The crude water extract was then
dried under vacuum at 50°C to yield the water-soluble
fraction (WtF, 16.5 g). The water-soluble fraction (WtF)
was stored in a capped container and maintained at 4°C.
This product was obtained from Professor Shorong-Shii
Liou (College of Pharmacy, Tajen University, Pingtung,
Taiwan). The major active principles quantified in this
product were salidroside (8.4 mg/g) and p-tyrosol
(1.9 mg/g) as described in previous reports [21,22].
Animal models
Ten-week-old male Wistar rats weighing 250 to 300 g
were obtained from the Animal Center of National
Cheng Kung University Medical College. The diet of the
animals used for the study was standard laboratory diet.
The number of animals for each group of experiment is
eight. STZ-diabetic rats were induced by intravenous
injection (i.v.) of STZ (65 mg/kg) into Wistar rats ac-
cording to the previous method [23]. Animals were con-
sidered to be type-1 diabetes- like model if they showed
plasma glucose concentrations of 20 mM or greater in
addition to polyuria and other diabetic features accord-
ing to previous reports [24-30]. All studies were carriedout 2 weeks after the injection of STZ. The rats used in
the present study were maintained in accordance with
the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health, as well as the guide-
lines of the Animal Welfare Act and the study was
approved by the animal research ethics committee of
Tzu Chi College of Technology (TCCN-101006) which
consisted of Prof. Yang SC, Chen MS, Dai KF, Liu WT,
Wei TK, Cho LG, and Wu MY.
Laboratory determinations
The determination of plasma glucose was conducted ac-
cording to the previous study [31]. The concentration of
plasma glucose was measured by the glucose oxidase
method using an analyzer (Quik-Lab, Ames; Miles Inc.,
Elkhart, IN, USA). The determination of BER in samples
was carried out using a commercially available enzyme-
linked immunosorbent assay (Peninsula Laboratories,
Belmont, CA, USA).
Effect on plasma β-endorphin level in STZ-diabetic rats
After fasting overnight, STZ-diabetic rats received an
intraperitoneal treatment of rhodiola-water extract at
the desired doses. It has been documented that rats
receiving sodium pentobarbital showed no significant
change in the parameters measured in plasma [32].
Thus, animals were anesthetized with sodium pentobar-
bital (35 mg/kg i.p.) and blood samples (0.1 mL) were
coμlected from the femoral vein for measurement of
plasma glucose concentrations and β-endorphin (BER).
In the present study, rhodiola-water extract at 75 mg/kg
was found to produce the maximal plasma glucose-
lowering effect in STZ-diabetic rats 60 min after intra-
peritoneal injection. Thus, the effect of rhodiola-water
extract on plasma BER was determined using blood
samples collected at 60 min after the treatment. STZ-
diabetic rats that received an intraperitoneal treatment
of vehicle only (0.9% saline) were used as controls.
Further experiments were performed with the pretreat-
ment of inhibitors, such as the antagonists of opioid
μ-receptors cyprodime (1.0 mg/kg) purchased from
(Tocris Cookson, Bristol, UK). The antagonist was
injected intravenously into rats 30 min before the treat-
ment of rhodiola-water extract.
Adrenalectomy of STZ-diabetic rats
Bilateral adrenalectomy was performed using the dorsal
approach under pentobarbital anesthesia (30 mg/kg, i.p.)
as described previously [28]. Wistar rats to be adrenalec-
tomized were fed standard rat chow and 0.9% sodium
chloride in their drinking water ad libitum prior to sur-
gery. Wistar rats to receive a sham operation (controls)
were fed standard rat chow and water ad libitum prior
to surgery. Animals were allowed to recover for 2 weeks
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good health. Following recovery, diabetes was induced
by an injection of STZ as described above. The effect of
rhodiola-water extract at 75 mg/kg was determined
using blood samples collected at 60 min after the
treatment.
Quantitative reverse transcription-polymerase chain
reaction (qRT-PCR)
Total RNA was extracted from liver and soleus muscle
tissue samples using Trizol reagent (Invitrogen). Two
microgram of total RNA was used for the reverse tran-
scription reaction, along with Superscriptase II (Invitro-
gen), oligo-dT, and random primers. The web-based
assay design software from the Universal Probe Library
Assay Design Center was used to design the TaqMan
primer pairs and to select the appropriate hybridization
probes. The reactions were performed in 20 μL of a mix-
ture consisting of 13.4 μL of PCR buffer, 0.2 μL of each
probe (20 μmol/L), 4 μL of LightCycler TaqMan (Roche
Diagnostics GmbH) and 2 μL of template cDNA. A
LightCycler Detection System (Roche Applied Science,
Germany) was used for amplification and detection. The
PCR reaction was carried out as follows: one cycle of
95°C for 10 min, 45 cycles of 94°C for 10 s, 60°C for
20 s, and 72°C for 1 s. The crossing point for each amp-
lification curve was determined using the second deriva-
tive maximum method. The concentration of each gene
was calculated with the aid of the LightCycler software
using the respective standard curve as reference. Relative
gene expression was expressed as a ratio of the target
gene concentration to the housekeeping gene 36B4
concentration. The sequences of primers were forward
5′-tttctgttggtatgcataatttgtaat-3′ and reverse 5′-ccagta-




Western blotting analysis was carried out as previously
described [28] and quantification was obtained from
three individual experiments. After homogenization of
liver and soleus muscle using a glass/Teflon homoge-
nizer, the homogenates (50 μg) were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis, and Western blot analysis was performed using
either an anti-rat GLUT 4 antibody purchased from
(Abcam, Cambridge, U.K) in soleus muscle or an anti-
rat PEPCK antibody from (Santa Cruz Biotechnology,
CA) in liver. The blots were probed with a goat poly-
clonal actin antibody from (Millipore, Billerica, MA,
USA) to ensure that the amount of protein loaded into
each lane of the gel was constant. Blots were incubated
with the appropriate peroxidase-conjugated secondaryantibodies. After removal of the secondary antibodies,
the blots were washed and developed using the ECL-
Western blotting system. Densities of the obtained
immunoblots at 45 KDa for GLUT 4, 69.5 KDa for
PEPCK, and 43 KDa for actin were quantified using laser
densitometer.
Statistical analysis
The plasma glucose-lowering activity of rhodiola-water
extract was calculated as the percentage decrease of the
initial glucose value according to the formula: (Gi −Gt)/
Gi × 100%, where Gi is the initial glucose concentration
and Gt is the plasma glucose concentration after treat-
ment of rhodiola-water extract. Data are expressed as
the mean ± S.E.M. for the number (n) of animals in the
group as indicated in tables and figures. Differences
among groups were analyzed by one-way ANOVA. The
Dunnett range post hoc comparisons were used to
determine the source of significant differences where
appropriate. A p-value of 0.05 or less was considered
statistically significant.
Results
Effects of rhodiola-water extract on plasma glucose
concentration and plasma β-endorphin-like immunoreac-
tivity (BER) level in STZ-diabetic rats
STZ-diabetic rats treated with rhodiola-water extract at
50 mg/kg through intraperitoneal injection produced the
plasma glucose-lowering activities as 8.3 ± 1.2% at
30 min later, 22.1 ± 0.8% at 60 min later, 18.7 ± 1.4% at
90 min later and 6.7 ± 2.1% at 120 min later (n = 8).
Then, we applied it at the most effective of time point in
following experiments. After 60 minutes, rhodiola-water
extract shows the plasma glucose-lowering activities as
11.6 ± 1.1%, 21.1 ± 0.9%, 32.9 ± 3.2% in STZ-diabetic rats
after an intraperitoneal (i.p.) injection at 35 mg/kg,
50 mg/kg or 75 mg/kg, respectively (n = 8). Rhodiola-
water extract at 75 mg/kg significantly lowered the
plasma glucose concentration from 381.4 ± 5.7 mg/dL
to 250.1 ± 11.2 mg/dL (p < 0.001; n = 8) as shown in
Figure 1A. Also, a dose-dependent increase of plasma
BER level was observed in parallel in STZ-diabetic rats
receiving rhodiola-water extract at same dosing from
35 mg/kg to 75 mg/kg (Figure 1B). Rhodiola-water ex-
tract at 75 mg/kg increased the plasma BER level from
basal level of 66.0 ± 0.9 pg/mL to 80.0 ± 1.4 pg/mL in
STZ-diabetic rats.
Effect of opioid μ-receptor blockade on rhodiola-water
extract-induced plasma glucose lowering action in
STZ-diabetic rats
As shown in Figure 2, the inhibitory effect of cyprodime
on the plasma glucose-lowering activity of rhodiola-
water extract in STZ-diabetic rats was produced in a
Figure 1 Effects of rhodiola-water extract on plasma glucose concentration and plasma β-endorphin level in STZ-diabetic rats. (A) The
plasma glucose lowering activity produced by rhodiola-water extract through an intraperitoneal (i.p.) injection into STZ-diabetic rats. (B) Plasma
β-endorphin-like immunoreactivity (BER) level in STZ-diabetic rats receiving i.p. injection of rhodiola-water extract. Values of mean and bar of S.E.
M. were obtained from each group of 8 rats. Vehicle only (0.9% saline) was given at the same volume. **p < 0.01 and ***, p < 0.001 versus data
from animals treated with vehicle (0).
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cyprodime, the plasma glucose concentration in rats
treated with 75 mg/kg rhodiola-water extract was
358.8 ± 7.6 mg/dL, which was not statistically different
with the vehicle-treated STZ-diabetic rats (365.1 ±
5.5 mg/dL). However, cyprodime alone did not affect
basal plasma glucose levels in STZ-diabetic rats.
Bilateral adrenalectomy of STZ-diabetic rats abolishes the
effects of rhodiola-water extract on plasma glucose and
BER levels
Bilateral adrenalectomy was performed in STZ-diabetic
rats. Two weeks after adrenalectomy, there were no sig-
nificant differences in the basal plasma levels of glucoseFigure 2 Effect of opioid μ-receptor blockade on rhodiola-water extra
The antagonist was given by an intravenous (i.v.) injection at 30 min before
water) was given at same volume. Values (mean ± S.E.M.) were obtained fr
data from vehicle-treated STZ-diabetic rats. ##, p < 0.01 and ###, p < 0.001 c
STZ-diabetic rats.and BER between sham-operated and adrenalectomized
STZ-diabetic rats (Table 1). However, the actions of
rhodiola-water extract regarding the lowering of plasma
glucose and the elevation of plasma BER levels were
abolished by bilateral adrenalectomy in STZ-diabetic
rats while both were unchanged in the sham-operated
STZ-diabetic rats (Table 1).
Effect of opioid μ-receptor blockade on rhodiola-water
extract-induced changes of GLUT 4 in skeletal muscle and
hepatic PEPCK in STZ-diabetic rats
Treatment of STZ-diabetic rats with rhodiola-water
extract (75 mg/kg) three times daily for 3 days resulted
in an elevation of GLUT 4 expression level in skeletalct-induced plasma glucose lowering action in STZ-diabetic rats.
the injection of rhodiola-water extract. Vehicle (0.9% NaCl in distilled
om each group of 8 rats. **, p < 0.01 and ***, p < 0.001 compared with
ompared with data from rhodiola-water extract (75 mg/kg)-treated
Table 1 Effect of adrenalectomy on the rhodiola-water
extract-induced changes of β-endorphin-like immunore-







Basal 378.6 ± 5.3 375.0 ± 4.6
Vehicle 370.5 ± 6.9 366.5 ± 5.0
Rhodiola-water
extract (75 mg/kg)
254.0 ± 2.4*** 373.5 ± 5.8
Plasma BER (pg/mL)
Basal 70.5 ± 2.1 69.8 ± 1.2
Vehicle 68.5 ± 1.8 69.0 ± 1.4
Rhodiola-water
extract (75 mg/kg)
84.3 ± 1.3*** 68.7 ± 1.2
Blood samples from STZ-diabetic rats receiving an intraperitoneal injection of
rhodiola-water extract or a vehicle-treated control were used for determination
of β-endorphin-like immunoreactivity (BER) and the plasma glucose concentra-
tion. Vehicle (0.9% saline) was given at the same volume. Values (mean ± S.E.
M.) were obtained from each group of eight rats. Basal level shows the value
from fasted animals without treatment. ***p < 0.001 versus basal value in
each group.
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(1.0 mg/kg) (Figure 3A). In addition, the expression
level of PEPCK in liver of STZ-diabetic rats was
increased to about 2.2 folds of that in non-diabetic
rats. The reduction of PEPCK expression by rhodiola-
water extract (75 mg/kg) in diabetic rats was observed
and this action was also attenuated by cyprodime
(Figure 3B).Figure 3 Effect of opioid μ-receptor blockade on rhodiola-water extra
PEPCK in STZ-diabetic rats. (A) The mRNA level of GLUT 4 in skeletal mu
rhodiola-water extract only or with cyprodime in combination, three times
isolated from STZ-diabetic rats receiving same treatment with rhodiola-wat
then collected for qRT-PCR analysis. Lane1, vehicle-treated Wistar rats; lane2
(75 mg/kg)-treated STZ-diabetic rats; lane 4, rhodiola-water extract (75 mg/
expressed as mean with standard error (SE) (n = 6 per group) is indicated in
lane 1. ##, p < 0.01 and ###, p < 0.001 compared with data obtained from laEffect of opioid μ-receptor blockade on rhodiola-water
extract-induced changes of protein levels of GLUT 4 in
skeletal muscle and hepatic PEPCK in STZ-diabetic rats
In Western blotting analysis, continuous treatment with
rhodiola-water extract (75 mg/kg) increased the GLUT 4
protein level in skeletal muscle. Pretreatment of STZ-
diabetic rats with cyprodime (1.0 mg/kg) abolished this
action of rhodiola-water extract (Figure 4A). Similarly,
the protein level of PEPCK in liver of STZ-diabetic rats
was raised to approximately 1.8 folds of that in
non-diabetic rats. The protein level of hepatic PEPCK
in diabetic rats was reversed by similar treatment
with rhodiola-water extract to normal level and this
action was also abolished by cyprodime (Figure 4B).
The data for quantification of GLUT 4 and PEPCK
protein levels were indicated in Figure 4A and
Figure 4B, respectively.
Discussion
In the present study, rhodiola-water extract lowers
plasma glucose concurrently with an increase of plasma
BER in STZ-diabetic rats. Both effects of rhodiola-water
extract are dose-dependent in same dose ranges. STZ-
diabetic rats are widely used as type-1 like diabetic ani-
mal model to investigate hyperglycemia [33]. Therefore,
the plasma glucose-lowering and BER-elevating actions
of rhodiola-water extract are concluded to occur under
the lacking of insulin. When treated with rhodiola-water
extract, STZ-diabetic rats provide a suitable model to
explore the phenomena that the reduction of plasma
glucose concentrations and increased BER are associated
in diabetic rats.ct-induced changes of GLUT 4 in skeletal muscle and hepatic
scle isolated from STZ-diabetic rats receiving treatment with
daily for 3 days. (B) The mRNA level of PEPCK expression in liver
er extract only or with cyprodime in combination. The samples were
, vehicle-treated STZ-diabetic rats; lane 3, rhodiola-water extract
kg) plus cyprodime (1.0 mg/kg)-treated STZ-diabetic rats. Data are
each column. ***, p < 0.001 compared with data obtained from
ne 2.
Figure 4 Effect of opioid μ-receptor blockade on rhodiola-water extract-induced changes of protein levels of GLUT 4 in skeletal muscle
and hepatic PEPCK in STZ-diabetic rats. (A) The representative response of protein level for GLUT 4 or actin in skeletal muscle isolated from
STZ-diabetic rats receiving treatment with rhodiola-water extract only or with cyprodime in combination, three times daily for 3 days. (B) The
representative response of protein level for PEPCK or actin in liver isolated from STZ-diabetic rats receiving same treatment with rhodiola-water
extract only or with cyprodime in combination. Lane1, vehicle-treated Wistar rats; lane2, vehicle-treated STZ-diabetic rats; lane 3, rhodiola-water
extract (75 mg/kg)-treated STZ-diabetic rats; lane 4, rhodiola-water extract (75 mg/kg) plus cyprodime (1.0 mg/kg)-treated STZ-diabetic rats.
Quantification of protein level using GLUT 4/actin or PEPCK/actin showing mean with standard error (SE) (n = 6 per group) in each column is
indicated in the lower panel. **, p < 0.01 and ***, p < 0.001 compared with data obtained from lane 1. #, p < 0.05, ##, p < 0.01 and ###, p < 0.001
compared with data obtained from lane 2.
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nized to be mediated by the opioid μ-receptors including
the regulation of glucose homeostasis [34,35], but the
mediation of opioid delta-receptor located in skeletal
muscle regarding to the hypoglycemic effect of BER has
also been demonstrated [36,37]. Actually, it has been
indicated that the expression of β-endorphin sensitive
receptor on skeletal muscle is vastly increased in type 1
and type 2 diabetic animals [38,39]. Moreover, the
increase of hepatic opioid μ-receptors was related to
diabetic hyperglycemia [40]. Thus, opioid μ-receptor
blockade was employed to evaluate the involvement of
this receptor in rhodiola-water extract-induced plasma
glucose lowering action in STZ-diabetic rats. The blood
glucose lowering effect of rhodiola-water extract is simi-
lar to meforminin in STZ-diabetic rats as described in
previous reports [41,42]. Cyprodime, the selective opioid
μ-receptor antagonist, has been shown to effectively
abolish the activation of opioid μ-receptors [43,44]. The
ability of rhodiola-water extract to decrease plasma
glucose was actually suppressed by blockade of opioid
μ-receptors with cyprodime. These findings demonstrate
the activation of opioid μ-receptors through increased cir-
culating β-endorphin in the plasma glucose lowering ac-
tion of rhodiola-water extract in diabetic rats. Similar
action was also observed in another herbal principle [45].
Endogenous opioids can be released into the blood-
stream from glands other than the pituitary gland [46],
and the secretion of opioids from the adrenal gland was
observed to foster a reduction in plasma glucose in STZ-diabetic rats [28]. Thus, bilateral adrenalectomy was per-
formed in the present study to verify that the source of the
increased plasma BER observed in STZ-diabetic rats in re-
sponse to rhodiola-water extract was the adrenal gland. As
shown in Table 1, the plasma glucose lowering action and
the increase of BER induced by rhodiola-water extract in
STZ-diabetic rats were both attenuated by adrenalectomy.
Thus, secretion of endogenous β-endorphin from adrenal
gland is responsible for the plasma glucose lowering action
of rhodiola-water extract in STZ-diabetic rats. Decrease of
plasma glucose by β-endorphin has been mentioned in
previous reports [47,48].
In diabetes, hyperglycemia is considered the conse-
quence of increased hepatic glucose output and decreased
peripheral glucose uptake [49,50]. Insulin deficiency is
associated with changes in hepatic metabolism including
increased expression of PEPCK that is a key enzyme of
hepatic carbohydrate metabolism [49,51]. Additionally,
decreased expression of skeletal muscle GLUT 4 in dia-
betes resulted in the reduction of insulin-mediated glucose
uptake into skeletal muscle [52]. It was interesting to as-
certain whether rhodiola-water extract produced plasma
glucose lowering action in diabetic rats by overturning the
diabetes dependent reduction of GLUT 4 expression and/
or increase in PEPCK expression. To provide sample time
for alterations in gene expression, STZ-diabetic rats re-
ceived the repeated treatment rhodiola-water extract for 3
days. Under these conditions, the increase in hepatic
PEPCK gene expression due to hyperglycemia was abol-
ished by rhodiola-water extract. The decrease of GLUT 4
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same repeated treatment rhodiola-water extract. These
findings suggest that rhodiola-water extract shows plasma
glucose lowering action due to changes in the expressions
of hepatic PEPCK and muscle GLUT 4 in an insulin-
independent manner.
It has been indicated that endogenous β-endorphin via
activation of opioid μ-receptors located in peripheral tis-
sues was found to serve as a positive regulator of glucose
utilization and a negative modulator of hepatic gluco-
neogenesis in the insulin-deficient state [20,53]. Opioid
μ-receptors antagonist was therefore used to evaluate
the involvement of opioid μ-receptors in the effects of
rhodiola-water extract on metabolic gene expression in
diabetic rats. Actions of rhodiola-water extract regarding
the increase of GLUT 4 expression in skeletal muscle
and decrease of PEPCK expression in liver were abol-
ished in STZ-diabetic rats with the blockade of opioid
μ-receptors using antagonist (Figure 3). Furthermore,
elevation of GLUT 4 protein expression and suppression
of PEPCK protein expression in STZ-diabetic rats by
rhodiola-water extract were also blocked by the same
antagonist named cyprodime (Figure 4).
It has been reported that PKC is involved in the rate-
limiting step in GLUT4 mRNA expression [54,55]. Also,
the PLC–PKC pathway is mediated in opioid μ-receptor
activation [20,44]. Thus, this pathway is involved in the
regulation of GLUT4 gene expression, although the
detailed mechanism(s) need more investigations in the
future. Our data also consistent with the report showing
that opioid μ-receptor activation might act as a negative
regulator to modify the gene expression of PEPCK in
insulin-deficient state [19,56]. However, the mediation of
PLC-PKC pathway in regulation of PEPCK gene expres-
sion is still unclear [57]. Thus, the signals from opioid
μ-receptor activation for regulation of hepatic PEPCK
gene expression during the absence of insulin need to
clarify in the future. Taken together, the normalizations
of hepatic PEPCK and muscle GLUT 4 expressions in
STZ-diabetic rats by rhodiola-water extract are mainly
mediated via an activation of opioid μ-receptors mainly
through the released endogenous β-endorphin.
Many ingredients are mentioned in rhodiola [58]
including glycosides, flavonoids, phenilpropanoids, and
others [59]. Also, another plant of the same genus
showed merit in reduction of plasma glucose in type-2
diabetic animals [60]. Thus, it is important to find out
the effective ingredients and/or related metabolites in
this action of rhodiola in the future.
Conclusions
In conclusion, our results suggest that rhodiola-water
extract may enhance the secretion of endogenous
β-endorphin from adrenal gland of STZ-diabetic rats.The plasma glucose lowering action of rhodiola-water
extract is mainly mediated by β-endorphin release
through an activation of opioid μ-receptors to achieve
the higher of GLUT 4 gene expression and/or the
decrease of hepatic PEPCK gene expression. Therefore,
these findings provide evidence in support of rhodiola-
water extract as the agent for handling of hyperglycemia
in diabetic disorders in rats. However, the blood glucose
lowering effect of rhodiola and/or active ingredient(s) on
human needs more investigations in the future.
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